COMPLETE TRADING ANALYSIS: CASSAVA SCIENCES INC. (SAVA)

Multi-Agent TradingAgents Analysis Report

Date: December 6, 2025 | Price: $2.89 (Dec 2) to $3.19 (User Quoted)

EXECUTIVE SUMMARY

FINAL VERDICT: STRONG AVOID - DO NOT ENTER POSITION

Investment Classification: PURE SPECULATION WITH EXISTENTIAL RISK Recommended Action: Do NOT allocate 32.3% portfolio to SAVA. REJECT this trade entirely. Conviction Level: ABSOLUTE (AVOID) Risk Assessment: EXTREME - Company facing potential delisting/bankruptcy

CRITICAL OVERRIDE: Despite user's ultra-aggressive profile, this position violates fundamental risk management principles. The 32.3% allocation to a stock trading at $2.89-$3.19 with failed Phase 3 trials, SEC fraud settlement, and no viable product pipeline represents capital destruction, not volatility trading.

FINAL INVESTMENT DECISION

GRAHAM'S THREE-PART TEST: FAILED CATASTROPHICALLY

Classification: TERMINAL SPECULATION - Not investment, not even rational speculation

TRADING DESK DECISION MATRIX

Graham's Final Checks

Risk-Adjusted Position Analysis

User's Proposed Position:

• Allocation: 32.3% of portfolio (€411 / ~128 shares at $3.19)
• Trading Window: December 8-19, 2025 (2 weeks)
• Strategy: Volatility swing play on negative beta

Trading Desk Override:

• Recommended Allocation: 0% (Complete rejection)
• Maximum Tolerable (if insisted): 2-3% (€25-€40 max, ~8-12 shares)
• Rationale: Even for ultra-aggressive profile, 32% allocation to penny biotech with failed trials is portfolio suicide

PHASE 1: ANALYST TEAM SUMMARIES

1. Stock Data Analyst - CRITICAL RED FLAGS

Current Market Data (December 2025):

• Price: $2.89 (Dec 2) / $3.19 (current quote) - penny stock territory
• 52-Week Range: $1.15 - $33.98 (currently -91% from highs)
• Market Cap: $139.6M (down from $1B+ in November 2024)
• Volatility Metrics:
  • Beta: 2.09 (extreme volatility vs market)
  • Historical Volatility: 100-108% (catastrophic swings)
  • Daily Volatility: 6.18% (last week average)
  • 52-Week Price Collapse: -96.5% from high

Recent Price Action:

• November 2024: Crashed 80%+ in single day on Phase 3 failure
• March 2025: Dropped 33% on program discontinuation
• December 2025: Trading near 52-week lows

Key Findings:

• Stock behaves like a binary biotech lottery ticket
• Extreme volatility creates illusion of "volatility trading opportunity"
• Reality: Each spike represents desperate retail hoping for miracle

2. Fundamental Analyst (Graham Criteria) - UNCONDITIONAL REJECT

Graham Number Calculation: NOT APPLICABLE (Negative Earnings)

Intrinsic Value Analysis:

Current Assets: ~$106M cash (Q3 2025)
Total Liabilities: $31.25M litigation contingency + operational liabilities
Shares Outstanding: 48.11M

Book Value per Share: ~$1.50-$2.00 (estimated)
Current Price: $2.89-$3.19
Price-to-Book: 1.5-2.1x

Earning Power: NEGATIVE (no revenue, R&D shuttered)
Expected 2026 Cash Burn: $40-$60M (depending on epilepsy trial)
Cash Runway: 18-24 months maximum (with no FDA approval)

Graham Defensive Investor Scorecard: 0/7 Criteria

SCORE: 0/7 - COMPLETE FAILURE

Biotech-Specific Fundamental Analysis:

Pipeline Status:

1. Simufilam for Alzheimer's Disease: FAILED Phase 3 (November 2024)

   • Primary endpoint: NO benefit vs placebo
   • Program: DISCONTINUED (Q2 2025)
   • Value: $0

2. Simufilam for TSC-Related Epilepsy: DELAYED

   • Status: FDA requires additional safety data (December 2, 2025)
   • Timing: Proof-of-concept study H1 2026 (maybe)
   • Probability of Success: <5% (same drug that failed Alzheimer's)
   • Value: Speculative, near-zero

Cash Position & Runway:

• Q3 2025 Cash: $106.1M
• Q4 2025 Estimated Cash: $92-96M
• Quarterly Burn Rate: $10-15M (reduced after Alzheimer's shutdown)
• Cash Runway: 6-8 quarters (18-24 months) at current burn
• CRITICAL: If epilepsy trial proceeds, burn accelerates

Regulatory & Legal Risks:

• SEC Fraud Settlement: $40M paid (September 2024) - no admission of wrongdoing
• Class Action Lawsuit: Filed January 2025, ongoing
• DOJ Charges: Dropped October 2025 (against researcher, not company)
• FDA Credibility: Severely damaged by fraud allegations and trial failures

Fundamental Verdict: This is not a company—it's a cash pile ($106M) wrapped in litigation ($31M contingency), burned by controversy (fraud settlement), with one failed drug trying a Hail Mary pivot to epilepsy. Graham would call this "speculation of the worst kind."

Margin of Safety: NEGATIVE ∞

• No earnings = no margin to calculate
• Cash value ~$2.20/share, but evaporating at $0.20-$0.30/quarter
• Even at $2.89, paying premium to disappearing cash

3. Technical Analyst (2-Week Swing Trade) - TIMING EXTREMELY POOR

Chart Analysis (December 2025):

Trend:

• Long-term: CATASTROPHIC DOWNTREND (from $33.98 to $2.89 = -91%)
• Medium-term: BEAR FLAG consolidation at lows
• Short-term: DEAD CAT BOUNCE potential, but into resistance

Key Technical Levels:

Momentum Indicators:

RSI (Relative Strength Index):

• User states: 60.7
• ANALYSIS: If true, RSI 60.7 near $3.19 suggests weak bounce into resistance
• Stock has shown RSI can whipsaw 20-80 in single sessions (100%+ volatility)
• Current RSI means NOT oversold - limited "bounce" fuel

MACD:

• Likely negative (no data, but inferred from downtrend)
• Death cross occurred November 2024 and never recovered

Bollinger Bands:

• User states: 82.7% historical 2-week range (extreme volatility)
• ANALYSIS: This confirms daily swings of ±10-20% are normal
• Current consolidation suggests coiling for next move (likely DOWN given fundamentals)

Volume Analysis:

• Post-crash volume: Declining (retail capitulation)
• Current volume: Low (no institutional interest)
• RED FLAG: Low volume + consolidation at lows = breakdown risk

ATR (Average True Range):

• User states: 7.64%
• ANALYSIS: Daily moves of ±7-8% are normal
• For 2-week trade: Expected range = ±15-20% from entry
• At $3.19: Potential range $2.55-$3.83
• PROBLEM: Downside risk ($2.55) hits COVID-level lows

Technical Verdict for Dec 8-19 Trading Window:

Entry Points (if proceeding despite warnings):

• Aggressive: $2.80-$3.00 (current lows, high risk)
• Conservative: Wait for break below $2.50 then bounce (better risk/reward)

Resistance Zones (Exit Targets):

• R1: $3.50 (psychological, minor)
• R2: $4.00-$4.30 (post-crash bounce level, STRONG)
• R3: $5.00+ (analyst targets, requires miracle news)

Support Zones (Stop Loss):

• S1: $2.50 (recent consolidation low)
• S2: $2.00 (psychological, critical)
• S3: $1.50 (approaching delisting territory)

2-Week Swing Trade Setup:

• ENTRY: $3.00-$3.20 (current levels)
• TARGET 1: $3.50 (+10-16%)
• TARGET 2: $4.00 (+25-33%)
• STOP LOSS: $2.50 (-16-21%)

Risk/Reward Ratio: 1:1 to 1:1.5 (POOR)

• Need 2:1 minimum for swing trades
• Current setup is coin flip, not edge

Timing Assessment: POOR ENTRY - Entering consolidation at lows with no catalyst and deteriorating fundamentals. Better to wait for:

1. Catalyst (FDA news on epilepsy trial) - but could be negative
2. Breakdown to $2.00-$2.50 then reversal (better risk/reward)
3. Short squeeze trigger (15.3% SI, but needs volume catalyst)

4. Sentiment Analyst (Controversy & Positioning) - MR. MARKET IS DELUSIONAL

Mr. Market's Mood: DESPERATELY HOPEFUL (Denial Stage)

Graham's Mr. Market Analysis: Mr. Market is offering you SAVA at $2.89-$3.19 for one of two reasons:

1. He's drunk on hopium about epilepsy approval (irrational)
2. He's panicking about bankruptcy and wants out (rational)

Given the fundamentals, Mr. Market at $2.89 is NOT offering a bargain—he's offering a trap.

Contrarian Signal: BE FEARFUL (Not greedy)

• When a stock crashes -91% and retail STILL holds with "bullish" sentiment (60/100 in March 2025), that's not contrarian opportunity—that's delusion
• True contrarians sold at $20-$30 before Phase 3 results
• Current "bulls" are bagholders averaging down, not smart money

Social Media Sentiment Analysis:

Reddit / WallStreetBets:

• Historical: Strong retail army 2021-2024
• Post-Crash: Devastated but defiant
• Current: Low mentions, mostly bagholders

StockTwits Sentiment:

• November 2024 (post-Phase 3 fail): 9/100 (extreme bearish)
• March 2025 (discontinuation): 60/100 (bullish) - DELUSIONAL
• December 2025: 40 mentions (1st percentile) - FORGOTTEN

Interpretation: Retail sentiment shifted from "extreme bearish" (9/100) after -84% crash to "bullish" (60/100) after program discontinuation. This is NOT rational—this is hope trading. Current low mentions (40/day) suggest retail has moved on, leaving only core bagholders.

Institutional Positioning:

Ownership Structure:

• Institutional: 32.49% (declining)
• Insiders: 72.66% (locked up, can't sell easily)
• Retail: ~0% (implies mostly insider-held)

Largest Holder:

• Eastbourne Capital Management: 29.25% (14.13M shares)
• CRITICAL: This is likely founder/management locked shares, not conviction buying

Insider Activity:

• Recent Activity: Insufficient data (likely none - who would buy?)
• Historical: CEO and CSO resigned July 2024 (after fraud settlement)

Institutional Verdict: Institutions have abandoned ship. 32% ownership sounds high, but 29% is single entity (likely founder). Smart money left at $10-$20.

Short Interest & Squeeze Potential:

Short Interest Metrics:

• Short Float: 15.3% (user data) to 31.5% (web search)
• Days to Cover: Unknown, but low volume makes this irrelevant
• Borrow Fee: Likely elevated (high risk)

Short Squeeze Analysis:

• Thesis: 15-31% SI + low float = squeeze potential
• Reality: Shorts are WINNING (stock at $2.89 from $33.98)
• Catalyst Needed: Major positive FDA news
• Probability: <5% (same drug failed Alzheimer's, why would epilepsy work?)

Short Squeeze Verdict: A short squeeze is NOT an investment thesis. It's a hope that other gamblers will drive price up so you can exit. At $2.89, shorts have 90%+ gains—they're not squeezable without genuine catalyst.

Controversy Impact:

Fraud Allegations:

• 2021: Whistleblower petition to FDA (research misconduct)
• 2022-2023: CUNY investigation found "egregious misconduct"
• September 2024: SEC fraud charges, $40M settlement (no admission)
• October 2025: DOJ dropped criminal charges (but damage done)

Reputational Damage:

• Scientific community: Simufilam mechanism questioned
• Investor community: Trust destroyed
• FDA: Higher scrutiny on any future submissions

Phase 3 Failure Context: The Phase 3 failure wasn't just "drug didn't work"—it validated skeptics who said the Phase 2 data was manipulated. This makes epilepsy pivot even less credible.

Sentiment Verdict: Mr. Market is NOT offering a bargain. He's offering a damaged, controversial, failed biotech at 3x cash burn rate with one Hail Mary left. Contrarian opportunity requires "hated but fundamentally sound"—SAVA is "hated AND fundamentally broken."

PHASE 2: BULL VS BEAR DEBATE

BULL CASE (Bull McInvestor) - "Binary Catalyst Upside"

Conviction: LOW-MEDIUM (3/10)

Core Thesis: SAVA at $2.89 is a binary bet on FDA approval for epilepsy indication. If simufilam works for TSC-related epilepsy, stock could 5-10x. Risk-reward favors small speculative position.

Top 5 Bull Arguments:

1. Lottery Ticket Valuation ($2.89 vs $33.98 highs)

   • Stock down -91% from highs, -96% from all-time highs
   • Market cap $139M vs $106M cash = only $33M enterprise value
   • "Paying almost nothing for epilepsy option value"

2. Short Squeeze Potential (15-31% Short Interest)

   • High short interest + low float + catalyst = squeeze fuel
   • Any positive FDA news could trigger covering
   • Historical precedent: SAVA squeezed from $5 to $146 in 2020-2021

3. Negative Beta (-1.09) = Portfolio Hedge

   • User's strategy: SAVA moves inverse to SPY
   • If market crashes, SAVA could rally (biotech flight-to-speculation)
   • Diversification benefit for bull market portfolio

4. Volatility = Trading Opportunity

   • 7.64% daily ATR = ±15-20% weekly swings
   • 82.7% historical 2-week range = massive swing potential
   • For 2-week trade, don't need FDA approval—just momentum

5. Turnaround Narrative

   • New CEO could refocus company
   • $106M cash allows 2-year runway for pivot
   • Epilepsy market ($2B+) less competitive than Alzheimer's
   • Simufilam mechanism might work for different indication

Bull's Expected Outcomes (2-week window):

Bull's Recommended Trade:

• Entry: $3.00-$3.20
• Position Size: 5-10% of portfolio (speculative allocation)
• Stop Loss: $2.50 (-17%)
• Target 1: $4.00 (+25-33%) - take 50% off
• Target 2: $5.00+ (+55-67%) - let rest ride

Bull's Caveats: "This is NOT investment—it's pure speculation. Only bet what you can afford to lose 100%. The thesis is binary: FDA approves epilepsy trial OR stock goes to zero. For ultra-aggressive trader seeking 5x SPY returns, this fits profile."

BEAR CASE (Bear McSafety) - "Value Trap Death Spiral"

Conviction: ABSOLUTE (10/10)

Core Thesis: SAVA is a failed biotech in terminal decline. The $2.89 price is NOT cheap—it's expensive for a company with no product, no pipeline credibility, and 18-24 months until cash runs out. This is not "volatility trading"—it's catching a falling knife with no handle.

Top 5 Bear Arguments:

1. Phase 3 Failure = Drug Doesn't Work

   • Simufilam showed ZERO benefit vs placebo in 52-week Alzheimer's trial
   • Not "missed by small margin"—complete failure
   • Same mechanism, same drug now pitched for epilepsy = same result likely
   • Probability epilepsy works: <5%

2. Fraud Settlement Destroys Credibility

   • SEC found company made "misleading statements" about Phase 2 results
   • $40M settlement (biggest expense Q2 2025)
   • CUNY found researcher committed "egregious misconduct"
   • FDA will scrutinize any future submission with extreme skepticism

3. Cash Burn Death Spiral

   • Q3 2025: $106M cash
   • Q4 2025: ~$92-96M (burning $10-14M/quarter)
   • If epilepsy trial starts: Burn rate doubles to $20-30M/quarter
   • Cash runs out Q2-Q3 2027, requiring dilutive financing at <$3 stock price

4. No Margin of Safety (Graham Violation)

   • Book value ~$1.50-$2.00/share (and shrinking with cash burn)
   • Current price $2.89 = paying premium to liquidation value
   • Liquidation value assumes you GET the cash—but $31M goes to litigation
   • True liquidation value: $1.50/share
   • Current price offers -48% "margin" (negative margin = value trap)

5. Negative Expected Value (Probabilistic Analysis)

   Scenario Analysis:
   
   A) FDA approves epilepsy trial, drug works (2% prob): $15-$20 → +400-600%
   B) FDA approves trial, drug fails (15% prob): $1.50 → -48%
   C) FDA delays/rejects trial (30% prob): $2.00 → -31%
   D) Cash burn forces dilution (30% prob): $1.00-$1.50 → -48% to -65%
   E) Bankruptcy/delisting (23% prob): $0.10 → -97%
   
   Expected Value = (0.02 × $17.50) + (0.15 × $1.50) + (0.30 × $2.00) + (0.30 × $1.25) + (0.23 × $0.10)
                  = $0.35 + $0.23 + $0.60 + $0.38 + $0.02
                  = $1.58
   
   Current Price: $2.89
   Expected Value: $1.58
   Expected Return: -45%
   

Bear's Additional Risks:

6. December 2 FDA Delay (Just Happened!)

   • FDA requested "additional information" for epilepsy trial
   • This delays H1 2026 study, burns more cash
   • Pattern: Every interaction with FDA results in delays/setbacks

7. Class Action Lawsuit (January 2025)

   • Securities fraud lawsuit filed
   • Lead plaintiff deadline February 10, 2025
   • Potential additional settlements/legal costs

8. Insider Exodus

   • CEO and CSO resigned July 2024
   • No insider buying (ever)
   • 72% insider ownership is LOCKED (can't sell), not conviction

9. Technical Breakdown Risk

   • RSI 60 near $3.19 = NOT oversold (more downside available)
   • Consolidation at lows typically breaks DOWN (not up)
   • Next support $2.00, then $1.15 (52-week low), then delisting

10. Opportunity Cost

    • Tying up 32% of portfolio in binary bet means MISSING real opportunities
    • SPY returns 10-15% annually with far less risk
    • Even "ultra-aggressive" doesn't mean "suicidal"

Bear's Expected Outcomes (2-week window):

Bear's Recommended Action: AVOID COMPLETELY. If gambler instinct cannot be resisted:

• Maximum Position: 2-3% of portfolio (€25-€40, not €411)
• Entry: Wait for breakdown to $2.00-$2.30, then bounce
• Stop Loss: $1.80 (strict, no exceptions)
• Target: $3.50-$4.00 (take profits immediately, don't get greedy)
• Better Alternative: Put that €411 into QQQ calls, NVDA, or literally anything with positive expected value

DEBATE OUTCOME

Prevailing View: BEARISH (8-2 Bears Win)

Points of Agreement:

1. SAVA is 100% speculation, 0% investment
2. Binary outcome: FDA approval OR bankruptcy
3. Extreme volatility (100%+ annual) creates trading illusion
4. Short interest (15-31%) could enable squeeze with catalyst
5. Current price ($2.89) near 52-week lows ($1.15)

Key Disagreement:

• Bull: "At $2.89, you're paying almost nothing for option value on epilepsy approval. Small bet, huge upside."
• Bear: "At $2.89, you're overpaying for worthless lottery ticket. Same drug failed Alzheimer's with fraud taint—epilepsy won't save it."

The Deciding Factor: Bear wins on EXPECTED VALUE math: Even assigning 15-20% probability to positive epilepsy outcome, expected value is $1.58 vs $2.89 price = -45% expected loss.

32.3% Portfolio Allocation:

• Bull: "Too high. Max 5-10% for binary speculation."
• Bear: "INSANE. Max 2-3%, preferably 0%."
• CONSENSUS: User's proposed 32.3% allocation is portfolio malpractice regardless of risk tolerance.

PHASE 3: RISK ASSESSMENT (Ultra-Aggressive Profile)

Risk Manager Analysis - THREE PERSPECTIVES

User Profile:

• Risk Tolerance: Ultra-aggressive
• Target: 5x SPY returns (50-75% annual)
• Max Loss: 15%
• Portfolio: €1,272
• Proposed SAVA Allocation: €411 (32.3%)
• Shares: ~128 at $3.19
• Timeframe: 2 weeks (Dec 8-19)

AGGRESSIVE RISK MANAGER - "REDUCE POSITION 90%"

Verdict: APPROVE 3% ALLOCATION ONLY

Risk Assessment: Even for ultra-aggressive profile, SAVA position is structurally flawed:

1. Position Sizing Violation

   • Proposed: 32.3% in single binary biotech
   • Maximum Acceptable: 10% for any single speculative position
   • Recommended: 3-5% for binary biotech
   • Action: Reduce from €411 to €38-€63 (~12-20 shares)

2. Stop Loss Math

   • Entry: $3.19
   • Stop: $2.50 (user's 15% max loss tolerance)
   • Dollar Risk per Share: $0.69
   • At 128 shares: $88 risk (€82) = 6.5% portfolio
   • PROBLEM: One bad day (-20% gap down) blows through stop, creates -13% portfolio hit

3. Risk/Reward Asymmetry

   • Upside (optimistic): $5.00 = +57% = €235 gain
   • Downside (realistic): $2.00 = -37% = €152 loss
   • Risk/Reward: 1.5:1 (ACCEPTABLE for aggressive, but only with proper sizing)
   • With 32% position: -37% = -12% portfolio damage (near max loss on ONE position)

4. Correlation Benefit (Negative Beta)

   • User claims beta -1.09 (inverse SPY correlation)
   • REALITY CHECK: Beta 2.09 in web search (positive, amplified)
   • Even if negative beta true, biotech doesn't follow market—follows FDA calendar
   • Hedge value: ZERO (correlation breaks down at critical moments)

5. Volatility Double-Edged Sword

   • User views 7.64% ATR as opportunity
   • Reality: 7.64% daily ATR = ±15% weekly swings
   • For 2-week hold: Expected range $2.70-$3.67 (±15%)
   • Problem: Range includes breakdown zone (<$2.50 stop)

Aggressive Risk Manager Recommendation:

APPROVED TRADE (Modified):

Position Size: €38-€63 (3-5% of €1,272 portfolio)
Shares: 12-20 shares
Entry: $3.00-$3.20 (current levels or slight pullback)
Stop Loss: $2.50 (HARD STOP, -21%)
Target 1: $4.00 (+25-33%) - sell 60% of position
Target 2: $5.00 (+55-67%) - sell remaining 40%
Risk Per Trade: €8-€13 (1% of portfolio)
Max Loss: €12-€18 (if stop hit)

Risk/Reward: 1:2 (acceptable for speculation)
Win Probability: 30%
Expected Value: +€2-€5 (marginal positive)

Conditions:

1. NO adding to position if it goes against you
2. NO averaging down
3. STRICT stop at $2.50 (no "wait and see")
4. Take profits at $4.00 (don't get greedy)
5. Consider this €50 "burnt" mentally (don't count on seeing it again)

NEUTRAL RISK MANAGER - "APPROVED 2% WITH SKEPTICISM"

Verdict: APPROVED 2% ALLOCATION (€25)

Risk Assessment: SAVA violates multiple prudent risk management principles, even for aggressive traders:

1. Fundamental Risk (Company Viability)

   • Product Pipeline: 0 approved drugs, 1 failed drug trying new indication
   • Cash Runway: 18-24 months
   • Revenue: $0
   • Path to Profitability: Requires miracle FDA approval
   • Risk Level: EXTREME (bankruptcy probability 20-30% within 2 years)

2. Regulatory Risk

   • FDA Scrutiny: Heightened due to fraud allegations
   • December 2 Setback: FDA requested more safety data (just happened)
   • Approval Probability: <10% for epilepsy (same mechanism that failed)
   • Risk Level: EXTREME

3. Liquidity Risk

   • Market Cap: $139M (micro-cap)
   • Daily Volume: Low (post-crash capitulation)
   • Bid-Ask Spread: Likely wide at $2-3 price
   • Risk Level: HIGH (hard to exit large position without slippage)

4. Event Risk

   • Binary Catalysts: FDA decision, cash raise, partnership (unlikely), bankruptcy
   • Timeframe: Any day (FDA calendar unpredictable)
   • Gap Risk: Stock can gap -30% overnight on bad news
   • Risk Level: EXTREME

5. Portfolio Concentration Risk

   • Proposed 32% allocation to single $2.89 biotech is INSANE
   • Violates "no more than 10% in any single speculative position" rule
   • For biotech with binary outcome: 2-5% maximum
   • Risk Level: CRITICAL VIOLATION

Neutral Risk Manager Recommendation:

APPROVED TRADE (Minimal Exposure):

Position Size: €25 (2% of portfolio)
Shares: 7-8 shares
Entry: $3.00 (wait for slight pullback from $3.19)
Stop Loss: $2.30 (-23% from entry)
Target: $4.50 (+50%)
Risk Per Trade: €5-€6
Max Loss: €6-€7

Risk/Reward: 1:2.2 (acceptable for binary speculation)
Win Probability: 20%
Expected Value: -€1 to €0 (neutral to slightly negative)

Mental Accounting: Consider this a "lottery ticket" - money is gone

Why 2% Instead of 0%: User has ultra-aggressive profile seeking 5x SPY. For such profile, small allocation to high-risk/high-reward binary bets is acceptable IF:

• Position sized to avoid portfolio damage (2% maximum)
• Thesis understood (this is gambling, not investing)
• Disciplined exit (strict stop loss)

Why NOT 32%: Because even ultra-aggressive ≠ stupid. Portfolio theory dictates:

• Max 10% in any single position
• Max 20% in any single sector
• Max 30% in speculative positions (combined)

32% in ONE failed biotech violates all three rules.

Alternative Suggestion: If user wants 32% in "ultra-aggressive volatility plays":

• 10% SAVA (if must include)
• 10% Crypto (BTC/ETH)
• 12% Growth options (NVDA, TSLA calls)

This maintains volatility exposure while diversifying binary risk.

CONSERVATIVE RISK MANAGER - "REJECT COMPLETELY"

Verdict: REJECT - DO NOT TRADE

Risk Assessment: SAVA position fails every risk management test:

Graham's Investment Principles (from /resources/intelligent-investor/):

1. "An investment operation is one which, upon thorough analysis promises safety of principal and an adequate return."

   • SAVA Analysis: ✓ Thorough analysis completed
   • Safety of Principal: ✗ FAILED (bankruptcy risk 20-30%)
   • Adequate Return: ✗ FAILED (expected value NEGATIVE)
   • CLASSIFICATION: SPECULATION (not investment)

2. "The chief losses to investors come from the purchase of low-quality securities at times of favorable business conditions."

   • SAVA Quality: LOW (failed drug, fraud settlement, no revenue)
   • Business Conditions: UNFAVORABLE (FDA skeptical, cash burning)
   • GRAHAM'S WARNING APPLIES DIRECTLY

3. "Margin of safety is the thread that runs through all investment policy."

   • SAVA Margin of Safety: NEGATIVE
   • Price $2.89 vs Liquidation Value $1.50 = -48% "margin"
   • NO MARGIN EXISTS

4. "Outright speculation is neither illegal, immoral, nor (for most people) fattening to the pocketbook."

   • SAVA: Pure speculation on binary FDA outcome
   • Historical Record: Biotech speculation has 90% failure rate
   • GRAHAM'S SKEPTICISM WARRANTED

5. "Speculating when you think you are investing" is unintelligent speculation.

   • User Framing: "Volatility swing play" (sounds like trading strategy)
   • Reality: Binary bet on FDA approval for drug that already failed
   • RISK: User may not fully grasp this is 100% speculation

6. "Never mingle your speculative and investment operations in the same account, nor in any part of your thinking."

   • User's proposed 32% allocation blurs line between speculation and investment
   • At 32%, this becomes portfolio's CORE holding (unacceptable for speculation)
   • GRAHAM'S RULE: Speculation maximum 10% of portfolio, preferably <5%

Conservative Risk Manager's Quantitative Analysis:

Value at Risk (VaR) - 95% Confidence:

• Position: €411 (32.3% portfolio)
• Daily Volatility: 6.18%
• 2-Week Volatility: ~25% (6.18% × √10 trading days)
• VaR (95%): €411 × 0.25 × 1.65 = €169
• Interpretation: 5% chance of losing €169+ (13% of total portfolio) in 2 weeks

Sharpe Ratio (Risk-Adjusted Return):

Expected Return: -45% (from bear case probabilistic analysis)
Volatility: 100%
Risk-Free Rate: 4% (US Treasury)
Sharpe Ratio = (-45% - 4%) / 100% = -0.49

Interpretation: NEGATIVE Sharpe = destroying value on risk-adjusted basis

Kelly Criterion (Optimal Bet Size):

Win Probability: 20%
Win Payoff: +50% (to $4.50)
Loss Probability: 80%
Loss Payoff: -37% (to $2.00)

Kelly % = (0.20 × 0.50 - 0.80 × 0.37) / 0.50
         = (0.10 - 0.30) / 0.50
         = -0.40 = -40%

Interpretation: Kelly says BET AGAINST SAVA (short it), not go long!

Conservative Risk Manager Recommendation:

REJECT TRADE COMPLETELY:

Reasons:

1. Negative Expected Value: -45% expected return
2. Negative Sharpe Ratio: Destroying value per unit of risk
3. Negative Kelly Criterion: Math says short, not long
4. Failed Graham Tests: 0/7 defensive criteria, no margin of safety
5. Catastrophic Position Size: 32% violates every diversification principle
6. Binary Risk: Single FDA decision determines 100% vs 0% outcome
7. Liquidity Risk: Micro-cap biotech, hard to exit in panic
8. Regulatory Risk: FDA skeptical post-fraud
9. Reputational Risk: Scientific community doubts mechanism
10. Opportunity Cost: €411 in SPY would earn 2-3% in 2 weeks (4% annually) with far less risk

If User INSISTS on Speculating:

Maximum Acceptable Allocation: 0%
If gun to head: €12-€25 (1-2% of portfolio)
Mental Accounting: "This is money I'm donating to the biotech lottery. I expect to lose it."
Entry: $2.50 or below (wait for breakdown, don't chase)
Stop Loss: $2.00 (or first close below $2.30)
Target: $4.00 (sell 100% immediately, no greed)

Better Alternatives for Ultra-Aggressive Portfolio:

1. Leveraged ETFs: TQQQ (3x Nasdaq) - high volatility, but tracks productive assets
2. Growth Options: NVDA, TSLA calls - binary, but companies have revenue/earnings
3. Crypto: BTC, ETH - volatile, but network effects and adoption growing
4. Small-Cap Value: Screen for Graham net-nets - speculative, but margin of safety
5. Momentum Plays: Stocks breaking 52-week highs with volume - technical edge

All five alternatives offer:

• Positive expected value (unlike SAVA's -45%)
• Liquidity (unlike SAVA's micro-cap)
• No binary FDA risk
• No fraud baggage

Final Word (Conservative Manager): "The market can remain irrational longer than you can remain solvent. SAVA at $2.89 may look cheap, but it's actually expensive for a company with no product, no credibility, and no margin of safety. Graham would say: 'Price is what you pay, value is what you get.' At $2.89, you pay real money for imaginary value."

RISK MANAGER CONSENSUS

CONSENSUS RECOMMENDATION: 2-3% MAXIMUM (€25-€38)

UNANIMOUS REJECTION of 32.3% allocation: All three risk managers agree that 32% position in single failed biotech is portfolio malpractice, regardless of risk tolerance.

PHASE 4: TRADING DESK FINAL DECISION

THE VERDICT

DECISION: STRONG AVOID - DO NOT ENTER POSITION

Recommendation: 0% ALLOCATION (If trader absolutely insists: Maximum 2% / €25 / 8 shares)

COMPREHENSIVE DECISION MATRIX

Investment Fundamentals:

• Graham Scorecard: 0/7 (complete failure)
• Margin of Safety: NEGATIVE (-48% to liquidation value)
• Intrinsic Value: $1.50-$1.80 (price $2.89 = overvalued)
• Expected Return: -45% (probabilistic analysis)
• Classification: Pure speculation with existential risk

Technical Setup:

• Trend: Catastrophic downtrend (-91% from highs)
• Entry Timing: POOR (consolidation at lows, no catalyst)
• Risk/Reward: 1:1 to 1:1.5 (need 2:1 minimum)
• RSI: 60.7 (not oversold, limited bounce fuel)
• Next Move Probability: 60-65% downside, 35-40% upside

Sentiment/Positioning:

• Institutional: Abandoned (32% ownership mostly locked insiders)
• Retail: Delusional hopium (bagholders averaging down)
• Insider: Exodus (CEO/CSO quit July 2024)
• Short Interest: 15-31% (but shorts are winning)

Risk Assessment:

• Position Size: 32% violates all diversification rules
• Maximum Acceptable: 2-3% for binary speculation
• Stop Loss: $2.50 = -21%, but gap risk could blow through
• Catalyst Risk: FDA decision binary (95% chance of neutral/negative)
• Liquidity Risk: Micro-cap, hard to exit without slippage

POSITION SIZING ANALYSIS

User's Proposed Position:

Allocation: 32.3% (€411)
Shares: 128 at $3.19
Stop Loss: $2.50 (-21%)
Portfolio Impact (if stop hit): -7.1% total portfolio damage
Risk/Reward: 1:1.5 (target $4.75)

REJECTED - Reasons:

1. Single position >10% violates concentration risk rule
2. Biotech binary bet >5% is gambling, not trading
3. Stop loss at -21% could gap through on FDA news (actual loss -30-50%)
4. Portfolio damage of -7% on ONE trade is unacceptable

Trading Desk Approved Position (if insisted):

Allocation: 2% (€25)
Shares: 8 at $3.00-$3.20
Entry: Wait for $3.00 or breakdown to $2.50-$2.80 then reversal
Stop Loss: $2.30 (strict, hard stop)
Target 1: $4.00 (+33%) - sell 100%
Portfolio Impact (if stop hit): -0.5% (acceptable for speculation)
Risk/Reward: 1:2 (minimum acceptable)

Mental Accounting: This €25 is "burned" - do not expect to see it again
Thesis: Lottery ticket on FDA miracle, not investment

TRADE EXECUTION PLAN (IF PROCEEDING DESPITE REJECTION)

Phase 1: Entry (Dec 8-10)

DO NOT ENTER at current $3.19:

• RSI 60.7 = not oversold
• Consolidation at lows typically breaks down
• No catalyst to drive upside
• Overhead resistance $3.50-$4.00 heavy

WAIT for Better Entry:

Option A: Breakdown then Reversal (Preferred)

1. Wait for break below $2.50
2. Watch for capitulation volume spike
3. Enter on first daily close above $2.60
4. Stop loss $2.30
5. Target $3.50-$4.00

Option B: Breakout Entry (Higher Risk)

1. Wait for break above $3.50 with volume
2. Enter $3.55-$3.70
3. Stop loss $3.20
4. Target $4.50-$5.00

Option C: News Catalyst (Unpredictable)

1. FDA announces epilepsy trial approval
2. Enter on first pullback after spike
3. This is gambling on timing - NOT RECOMMENDED

Phase 2: Management (Dec 11-17)

Daily Monitoring:

• Check FDA.gov for SAVA announcements (daily 4pm ET)
• Monitor cash burn updates
• Watch for insider selling (sign of trouble)
• Track short interest changes (potential squeeze fuel)

Exit Triggers (SELL IMMEDIATELY):

1. FDA rejects/delays epilepsy trial further
2. Company announces cash raise (dilution)
3. Class action lawsuit update (negative)
4. Stock closes below $2.30 (stop loss)
5. ANY negative news (don't wait to understand it)

Profit-Taking Plan:

• First close above $3.80: Sell 50%
• First close above $4.50: Sell remaining 50%
• DO NOT hold through $5.00 hoping for $10 (greed kills)

Phase 3: Exit (Dec 17-19)

If Still Holding by Dec 17:

• Evaluate position: Are you up or down?
• If UP: Take profits (don't get greedy)
• If DOWN: Cut losses (don't average down)
• If FLAT: Consider exiting (opportunity cost)

2-Week Rule: This is 2-week SWING TRADE, not investment.

• Dec 19: EXIT regardless of outcome
• Do NOT fall in love with position
• Do NOT "give it more time"
• Move on to next opportunity

KEY RISKS TO MONITOR

CRITICAL (Check Daily):

1. FDA Calendar

   • Epilepsy trial decision (expected H1 2026, but could come earlier)
   • Any communication from FDA regarding safety concerns
   • REMS (Risk Evaluation Mitigation Strategy) requirements

2. Cash Position

   • Q4 2025 cash level (should report early Jan 2026)
   • If below $90M = runway concerns
   • If below $80M = dilution imminent

3. Legal Updates

   • Class action lawsuit developments (lead plaintiff deadline Feb 10, 2025)
   • Any new SEC/DOJ investigations
   • Settlement payments

IMPORTANT (Check Weekly):

4. Insider Activity

   • Form 4 filings (insider sales = very bearish)
   • Executive departures (more exodus = death spiral)

5. Short Interest

   • NASDAQ reports twice monthly
   • Rising SI = more bearish pressure
   • Falling SI = shorts covering (could squeeze)

6. Technical Breakdown Levels

   • $2.50 breakdown = next leg down
   • $2.00 psychological support
   • $1.50 approaches 52-week low
   • <$1.00 = delisting risk

MODERATE (Monitor):

7. Sector Sentiment

   • Biotech sector (IBB ETF) performance
   • Other Alzheimer's drug trials (sector contagion)
   • FDA approval trends (biotech)

8. Retail Sentiment

   • StockTwits sentiment score
   • Reddit mentions (WSB, biotech_stocks)
   • Message volume (apathy = death, frenzy = top)

GRAHAM'S CLOSING WISDOM

From The Intelligent Investor, Chapter on Margin of Safety:

"The chief losses to investors come from the purchase of low-quality securities at times of favorable business conditions. The purchasers view the current good earnings as equivalent to 'earning power' and assume that prosperity is synonymous with safety."

Applied to SAVA: SAVA represents the inverse but equally dangerous trap: purchasing low-quality securities at times of UNfavorable business conditions, viewing extreme cheapness as equivalent to "value" and assuming that a low price is synonymous with opportunity.

Graham's Warning:

"These securities do not offer an adequate margin of safety in any admissible sense of the term... The investor has never had a real safety margin to tide him through adversity."

At $2.89, SAVA offers:

• No margin of safety (trading above liquidation value)
• No earning power (negative earnings, no revenue)
• No business quality (failed drug, fraud settlement)
• No prospect for recovery (epilepsy pivot has <5% probability)

Graham's Three-Word Motto: MARGIN OF SAFETY

SAVA's Three-Word Reality: NO MARGIN EXISTS

FINAL RECOMMENDATION SUMMARY

For Trading Desk Record:

Risk Score: 10/10 (Maximum Risk)

Expected Outcome:

• Probability of Profit: 20-30%
• Probability of Loss: 70-80%
• Expected Return: -45%
• Expected Value: NEGATIVE

Recommendation: DO NOT TRADE. CAPITAL PRESERVATION TAKES PRIORITY.

ALTERNATIVE RECOMMENDATIONS

If User Wants Ultra-Aggressive 2-Week Swing Trades:

Better Alternatives (All Superior Risk/Reward):

1. QQQ Weekly Options (Tech Volatility)

   • Risk: Defined (option premium)
   • Reward: 50-200% on directional move
   • Liquidity: Excellent
   • Expected Value: Neutral to positive

2. NVDA (AI Leader Volatility)

   • Risk: Manageable with stops
   • Reward: Earnings catalysts, sector momentum
   • Fundamentals: Actual revenue, earnings, growth
   • Expected Value: Positive

3. TSLA (High Beta Large Cap)

   • Risk: High but manageable
   • Reward: Delivery numbers, Musk news flow
   • Volatility: Similar to SAVA but liquid
   • Expected Value: Neutral

4. Small-Cap Momentum Screen

   • Criteria: 52-week high breaks, volume surge, RS >70
   • Diversify: 5 positions × 6% = 30% allocation
   • Expected Value: Positive (momentum premium)

5. Biotech Basket (NOT Single Stock)

   • 10 biotechs × 3% each = 30%
   • Diversifies binary risk
   • Expected Value: Neutral (some win, some lose)

Why These Are Better:

• Diversification (not 32% single stock)
• Liquidity (can exit easily)
• Defined risk (options) or manageable (large caps)
• No fraud baggage
• Positive/neutral expected value (not -45%)

DISCLAIMER

This analysis represents a comprehensive multi-agent framework review of SAVA applying Benjamin Graham's value investing principles.

This is NOT financial advice.

• Past performance does not guarantee future results
• Biotech investments carry extreme binary risk
• FDA approval processes are unpredictable
• Always do your own research
• Consult qualified financial advisor before trading
• Never invest more than you can afford to lose completely

Specific SAVA Warnings:

• Stock may gap down -30-50% overnight on FDA news
• Cash burn may force dilutive financing at <$3
• Bankruptcy is realistic 20-30% probability
• No margin of safety exists at any price
• This is speculation, not investment

Graham's Final Test: "Would I be comfortable holding this for 10 years without looking at the price?"

SAVA Answer: Absolutely not. Company may not exist in 2 years, let alone 10.

Report Prepared By: TradingAgents Multi-Agent System Date: December 6, 2025 Analysts: Fundamental (Graham), Technical, Sentiment, Risk (3 profiles), Trading Desk Methodology: Benjamin Graham value investing principles + modern risk management

File: /home/pengacau/pasar-malam/output/SAVA_comprehensive_trading_desk_analysis_2025-12-06.md

APPENDIX: DATA SOURCES

Market Data:

• Current Price: $2.89 (Dec 2, 2025) to $3.19 (user quote)
• 52-Week Range: $1.15 - $33.98
• Market Cap: $139.6M
• Shares Outstanding: 48.11M
• Beta: 2.09 (web) / -1.09 (user claim - verify)

Financial Data:

• Q3 2025 Cash: $106.1M
• Q4 2025 Est. Cash: $92-96M
• Q3 Net Loss: $10.8M
• Litigation Contingency: $31.25M
• Quarterly Burn: $10-15M

Regulatory:

• Phase 3 Alzheimer's: FAILED (Nov 2024)
• Alzheimer's Program: DISCONTINUED (Q2 2025)
• Epilepsy Trial: DELAYED (Dec 2, 2025 - FDA requested more data)
• SEC Settlement: $40M (Sept 2024)
• Class Action: Filed Jan 2025

Ownership:

• Institutional: 32.49% (mostly Eastbourne 29%)
• Insider: 72.66% (locked, not conviction)
• Short Interest: 15.3% (user) to 31.5% (web)

Sentiment:

• StockTwits: 40 mentions (1st percentile - forgotten)
• Historical Sentiment: Ranged from 9/100 (bearish) to 60/100 (delusional bullish)
• Analyst Target: $5.10 average (range $2.02-$8.40)